"No time to lift
General Lifestyle Changes The GLP-1 Tracker follows GLP-1 users across several different lifestyle behaviors, such as exercise habits, alcohol and cannabis usage, supplement usage, and changes to well-being and mood
For subjects treated with the highest dose of tirzepatide (15 mg per week), the risk to develop any major adverse cardiovascular event (MACE-4 composed of myocardial infarction, stroke, hospitalization for angina, and all-cause death) was estimated at 050 (026095)
Not because the treatments are unpredictable, but because hair loss itself is not uniform
Currently, there is no direct evidence that GLP-1RA use contributes to progression of pancreatic cysts to PDAC, but this remains an important knowledge gap for future investigations considering the high prevalence of pancreatic cysts in the general population (~ 10% by age 50 and ~25% by age 70) 56